OncoMatch/Clinical Trials/NCT04414475
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Is NCT04414475 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Selinexor and Dexamethasone for multiple myeloma, refractory.
Treatment: Selinexor · Dexamethasone · Bortezomib — The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
refractory to previous treatment with at least 2 proteasome inhibitors (PIs)
Must have received: immunomodulatory agent
refractory to previous treatment with at least 2 immunomodulatory agent (IMiDs)
Must have received: anti-CD38 monoclonal antibody
refractory to previous treatment with at least 1 anti-cluster of differentiation (CD38) monoclonal antibody
Cannot have received: SINE compound (selinexor)
Prior exposure to a SINE compound, including selinexor
Lab requirements
Blood counts
ANC < 1000/mm^3, platelet count < 75,000/mm^3, hemoglobin < 8.5 g/dL [excluded]
Kidney function
estimated creatinine clearance of < 20 mL/min, calculated using Cockroft and Gault [excluded]
Liver function
total bilirubin >= 2x ULN (>= 3x ULN for participants with Gilbert's syndrome), AST >= 2.5x ULN, and ALT >= 2.5x ULN [excluded]
Inadequate hepatic, renal, or hematopoietic function as defined in exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04414475 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior SINE compound disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages